Company Research Report: Fresenius Kabi

Company Overview

• Name: Fresenius Kabi

• Mission: Committed to improving patient care with life-saving medicines and technologies for critically and chronically ill patients.

• Founded: 1999 (with roots stretching to 1912, originally established by Dr. Eduard Fresenius)

• Key People:

• President and CEO: Pierluigi Antonelli

• Chief Financial Officer & Chief Compliance Officer: Andreas Duenkel

• Chief Human Resources Officer: Helio Fujita

• President Pharma & Nutrition: Dr. Marc-Alexander Mahl

• President MedTech: Dr. Christian Hauer

• President Biopharma: Dr. Sang-Jin Pak

• Headquarters: Bad Homburg, Germany

• Number of Employees: More than 43,000 worldwide (2023)

• Revenue: More than €8 billion in sales (2023)

• Known For: Specializing in biopharmaceuticals, clinical nutrition, medical technologies, and I.V. generic drugs.

Products

Overview

Fresenius Kabi offers innovative solutions across Pharma, Nutrition, MedTech, and Biopharma, focusing on high-quality healthcare results.

Detailed Product Offerings

IV Therapy

• IV Drugs and Infusion Therapy Products: Critical for emergency medicine, surgery, and intensive care.

• IV Fluids: Utilized for situations like dehydration and blood loss; features include electrolyte solutions and colloids.

• IV Drugs Portfolio: Over 160 drugs in areas like oncology, anesthetics, analgesics, and critical care.

Medical Nutrition

• Enteral Nutrition (Fresubin®): Includes ready-to-drink beverages, yogurt-style supplements, and tube feeds for patients with insufficient oral intake.

• Parenteral Nutrition: For patients unable to absorb nutrients through the digestive tract; consists of intravenous infusions.

Medical Technologies

• Comprehensive products supporting infusion and nutritional therapies, blood and plasma centers, and cell therapies.

• Integration of connected systems for data management within healthcare settings.

Biopharma

• Development and commercialization of biopharmaceuticals, particularly biosimilars in autoimmune diseases and oncology.

Recent Developments

Product Launches and Innovations

• Biosimilars:

• Launch of Tyenne®, the third approved biosimilar in the U.S.

• Ustekinumab biosimilar Otulfi™ received FDA and European Commission approval for both subcutaneous and intravenous formulations.

Strategic Partnerships

• Signed a Development Agreement with Cellular Origins for scalable automation in cell and gene therapy manufacturing.

• Partnership with Formycon, resulting in U.S. FDA approval of OtulfiTM(ustekinumab-aauz).

Awards and Recognition

• Fresenius Kabi received a prestigious sustainability award at Berlin’s Sustainability Kongress 2024 for CO₂ reduction projects.

Other Notable Developments

• Introduction of "Vision 2026," a strategic framework aimed at enhancing efficiency in therapy and global healthcare access.

• Winning the Fresenius Kabi Clinical Nutrition Award for innovative research in medical nutrition.

Conclusion

Fresenius Kabi is a noteworthy leader in providing critical healthcare solutions globally, marked by its extensive network, innovation in pharmaceuticals and nutrition, and strategic advancements through partnerships and product developments.